BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Van Herck S, De Geest BG. Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics. Acta Pharmacol Sin 2020;41:881-94. [PMID: 32451411 DOI: 10.1038/s41401-020-0425-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Yang Y, Zhao T, Chen Q, Li Y, Xiao Z, Xiang Y, Wang B, Qiu Y, Tu S, Jiang Y, Nan Y, Huang Q, Ai K. Nanomedicine Strategies for Heating “Cold” Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC. Advanced Science. [DOI: 10.1002/advs.202202797] [Reference Citation Analysis]
2 Rajagopal P, Jayandharan GR, Maheswari Krishnan U. Polyketal-based nanocarriers: A new class of stimuli-responsive delivery systems for therapeutic applications. European Polymer Journal 2022;173:111290. [DOI: 10.1016/j.eurpolymj.2022.111290] [Reference Citation Analysis]
3 Li JH, Huang LJ, Zhou HL, Shan YM, Chen FM, Lehto VP, Xu WJ, Luo LQ, Yu HJ. Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy. Acta Pharmacol Sin 2022. [PMID: 35484402 DOI: 10.1038/s41401-022-00910-w] [Reference Citation Analysis]
4 Liu Y, Li H, Zhao H, Hao Y, Van Herck S, Xu Z, Wang G, Wang X, Zhang X, Ge X, Li X, Yang A, Chen H, Zou J, Wang W, De Geest BG, Zhang Z. In Situ Tumor Vaccination with Calcium-Linked Degradable Coacervate Nanocomplex Co-Delivering Photosensitizer and TLR7/8 Agonist to Trigger Effective Anti-Tumor Immune Responses. Adv Healthc Mater 2022;:e2102781. [PMID: 35285581 DOI: 10.1002/adhm.202102781] [Reference Citation Analysis]
5 Van Herck S, Feng B, Tang L. Delivery of STING agonists for adjuvanting subunit vaccines. Adv Drug Deliv Rev 2021;179:114020. [PMID: 34756942 DOI: 10.1016/j.addr.2021.114020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
6 Jeong S, Choi Y, Kim K. Engineering Therapeutic Strategies in Cancer Immunotherapy via Exogenous Delivery of Toll-like Receptor Agonists. Pharmaceutics 2021;13:1374. [PMID: 34575449 DOI: 10.3390/pharmaceutics13091374] [Reference Citation Analysis]
7 Manna S, Maiti S, Shen J, Du W, Esser-Kahn AP. Pathogen-like Nanoassemblies of Covalently Linked TLR Agonists Enhance CD8 and NK Cell-Mediated Antitumor Immunity. ACS Cent Sci 2020;6:2071-8. [PMID: 33274283 DOI: 10.1021/acscentsci.0c01001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Yu HJ, De Geest BG. Nanomedicine and cancer immunotherapy. Acta Pharmacol Sin 2020;41:879-80. [PMID: 32467567 DOI: 10.1038/s41401-020-0426-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]